Nachrichten zu Augmedix

Startseite > Aktien > Augmedix > Nachrichten

Aktie

ISIN: US05105P1075 WKN: A2QHRH SYM: AUGX Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

2,3300

USD

+0,43 %

+0,0100 USD

Letzter Kurs 02:00:00 Nasdaq

Geldkurs

13.09.24

2,3200

USD

127.900 STK

Briefkurs

13.09.24

2,3300

USD

9.500 STK

Augmedix Aktie kaufen

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Augmedix, Inc. (AUGX) 12.09.24 · newsfile · Augmedix
Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024 12.08.24 · globenewswire · Augmedix
Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024 06.08.24 · globenewswire · Augmedix
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Augmedix, Inc. Buyout 22.07.24 · newsfile · Augmedix
AUGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Augmedix, Inc. Is Fair to Shareholders 19.07.24 · Business Wire (engl.) · Augmedix
Augmedix to Join Forces with Commure 19.07.24 · globenewswire · Augmedix
Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments 20.06.24 · globenewswire · Augmedix
Augmedix Reiterates Second Quarter and Full Year 2024 Outlook 04.06.24 · globenewswire · Augmedix
Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer 29.05.24 · globenewswire · Augmedix
Augmedix Delivers 40% Revenue Growth for First Quarter of 2024 13.05.24 · globenewswire · Augmedix
Augmedix to Participate in Upcoming Investor Conferences in May and June 2024 03.05.24 · globenewswire · Augmedix
Augmedix to Announce First Quarter 2024 Financial Results on May 13, 2024 30.04.24 · globenewswire · Augmedix

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Augmedix, Inc. (AUGX) 100 Leser

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Augmedix, Inc. (AUGX) 100 Leser

Augmedix Delivers 40% Revenue Growth for First Quarter of 2024 584 Leser
Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician-Controlled Mobile ... 284 Leser
Augmedix to Participate in Upcoming Investor Conferences in May and June 2024 272 Leser
Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024 248 Leser
Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024 216 Leser
Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue 208 Leser
Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock 192 Leser
Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for ... 180 Leser
Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023 176 Leser
Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go 172 Leser